Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Inventory-to-Revenue : 1.31 (As of Mar. 2024)

---

Tianjin Chase Sun Pharmaceutical Co Inventory-to-Revenue Chart

---

Competitive Comparison of Tianjin Chase Sun Pharmaceutical Co's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Chase Sun Pharmaceutical Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

---

Tianjin Chase Sun Pharmaceutical Co's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Chase Sun Pharmaceutical Co's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tianjin Chase Sun Pharmaceutical Co's Inventory-to-Revenue falls into.

---

Tianjin Chase Sun Pharmaceutical Co Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Tianjin Chase Sun Pharmaceutical Co's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Tianjin Chase Sun Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

Tianjin Chase Sun Pharmaceutical Co  (SZSE:300026) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Tianjin Chase Sun Pharmaceutical Co's Days Inventory for the three months ended in Mar. 2024 is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Tianjin Chase Sun Pharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

Tianjin Chase Sun Pharmaceutical Co Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tianjin Chase Sun Pharmaceutical Co's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Total Inventories Revenue Days Inventory Cost of Goods Sold Inventory Turnover

---

Tianjin Chase Sun Pharmaceutical Co (SZSE:300026) Business Description

Executives

Yao Xiao Qing	Director
Chen Rui Qiang	Executives
Li Chun Xu	Executives
Lan Wu Jun	Directors, Directors, and Executives
Zheng Dan	Directors, executives
Zhang Kun	Executives
Gao Guo Wei	Executives
Shang Xiao Mei	Securities Affairs Representative
Sun Zhang Hai	Director
Wu Guang Ning	Supervisors
Wang Long	Executives
Liu Qiang	Supervisors
Ceng Guo Zhuang	Director
Su Bing Jun	Directors, executives
Nie Wei	Supervisors